Literature DB >> 28623715

Diosgenin glucoside provides neuroprotection by regulating microglial M1 polarization.

Shaoxia Wang1, Fujiang Wang2, Hongyun Yang1, Ruilin Li2, Hong Guo2, Limin Hu3.   

Abstract

The selective suppression of inflammatory factors in activated microglia, rather than totally inhibiting their activation, might be an effective means of slowing the progression of certain neurodegenerative diseases. Diosgenin glucoside (Dios) is a saponin compound extracted from Tritulus terrestris L. We found that Dios suppressed the synthesis of molecules that promote inflammation (M1 markers, such as NO, IL-6, and TNF-α) in rat microglia and BV-2 cells induced with lipopolysaccharides (LPS). In contrast, Dios had no effects on the cellular production of anti-inflammatory factors (M2 markers, such as IL-10, IL-1Rα and CD206) in LPS and IL-4 treated microglia. Dios repressed IκB-α, ERK MAPK and p38 MAPK phosphorylation, but did not affect JNK in LPS-activated microglia. We also found that conditioned medium obtained from cultures of BV-2 cells incubated with Dios plus LPS was markedly less neurotoxic than conditioned medium obtained from cultures of BV-2 cells incubated with LPS alone. In conclusion, this study demonstrated that Dios can selectively suppress the production/expression of pro-inflammatory M1 markers by activated microglia, without affecting M2 markers, and might provide neuroprotection by regulating microglial M1 polarization. Our results suggest that Dios can be used in treatment of various neuroinflammatory diseases mediated by microglia.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Diosgenin glucoside; Inflammation; Microglia; Neuroprotection

Mesh:

Substances:

Year:  2017        PMID: 28623715     DOI: 10.1016/j.intimp.2017.06.008

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  9 in total

1.  Water-Soluble Arginyl-Diosgenin Analog Attenuates Hippocampal Neurogenesis Impairment Through Blocking Microglial Activation Underlying NF-κB and JNK MAPK Signaling in Adult Mice Challenged by LPS.

Authors:  Bangrong Cai; Kyung-Joo Seong; Sun-Woong Bae; Min Suk Kook; Changju Chun; Jin Ho Lee; Won-Seok Choi; Ji-Yeon Jung; Won-Jae Kim
Journal:  Mol Neurobiol       Date:  2019-02-11       Impact factor: 5.590

2.  Neuroprotective role of Diosgenin, a NGF stimulator, against Aβ (1-42) induced neurotoxicity in animal model of Alzheimer's disease.

Authors:  Swati Som; Justin Antony; SPalanisamy Dhanabal; Sivasankaran Ponnusankar
Journal:  Metab Brain Dis       Date:  2022-01-13       Impact factor: 3.584

Review 3.  Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives.

Authors:  Prabhakar Semwal; Sakshi Painuli; Tareq Abu-Izneid; Abdur Rauf; Anshu Sharma; Sevgi Durna Daştan; Manoj Kumar; Mohammed M Alshehri; Yasaman Taheri; Rajib Das; Saikat Mitra; Talha Bin Emran; Javad Sharifi-Rad; Daniela Calina; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2022-05-29       Impact factor: 7.310

Review 4.  Contribution of macrophages to fetomaternal immunological tolerance.

Authors:  P Parasar; N Guru; N R Nayak
Journal:  Hum Immunol       Date:  2021-03-11       Impact factor: 2.850

Review 5.  Chemopreventive Effects of Phytochemicals and Medicines on M1/M2 Polarized Macrophage Role in Inflammation-Related Diseases.

Authors:  Yen-Chun Koh; Guliang Yang; Ching-Shu Lai; Monthana Weerawatanakorn; Min-Hsiung Pan
Journal:  Int J Mol Sci       Date:  2018-07-28       Impact factor: 5.923

6.  Design, Synthesis and Biological Evaluation of Diosgenin-Amino Acid Derivatives with Dual Functions of Neuroprotection and Angiogenesis.

Authors:  Desheng Cai; Jinchai Qi; Yuqin Yang; Wenxi Zhang; Fei Zhou; Xiaohui Jia; Wenbo Guo; Xuemei Huang; Feng Gao; Hongshan Chen; Tong Li; Guoping Li; Penglong Wang; Yuzhong Zhang; Haimin Lei
Journal:  Molecules       Date:  2019-11-07       Impact factor: 4.411

7.  Protective role of diosgenin against hyperglycaemia-mediated cerebral ischemic brain injury in zebrafish model of type II diabetes mellitus.

Authors:  Oyesolape B Oyelaja-Akinsipo; Enock O Dare; Deepshikha P Katare
Journal:  Heliyon       Date:  2020-01-31

8.  An update on the biological and pharmacological activities of diosgenin.

Authors:  Jae Kwang Kim; Sang Un Park
Journal:  EXCLI J       Date:  2018-01-02       Impact factor: 4.068

9.  Effect of Neurorepair for Motor Functional Recovery Enhanced by Total Saponins From Trillium tschonoskii Maxim. Treatment in a Rat Model of Focal Ischemia.

Authors:  Le Yang; Jian-Feng Lei; Jun-Yao Ouyang; Man-Zhong Li; Yu Zhan; Xue-Feng Feng; Yun Lu; Ming-Cong Li; Lei Wang; Hai-Yan Zou; Hui Zhao
Journal:  Front Pharmacol       Date:  2021-12-10       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.